Abstract | BACKGROUND:
Gastrectomy with D2 dissection and adjuvant chemotherapy is the standard treatment for locally advanced gastric cancer (LAGC) in Asia. However, administering chemotherapy with sufficient intensity after gastrectomy is challenging. Several trials demonstrated the efficacy of neoadjuvant chemotherapy (NAC). However, limited studies explored the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) evaluated the safety and efficacy of NAC-SOX in patients with LAGC aged ≥ 70 years. METHODS: Patients received three cycles of SOX130 ( oxaliplatin 130 mg/m2 on day 1, oral S-1 40-60 mg twice daily for two weeks every three weeks) as NAC, followed by gastrectomy with lymph node dissection. The primary endpoint was the dose intensity (DI). The secondary endpoints were safety, R0 resection rate, pathological response rate (pRR), overall survival, and relapse-free survival. RESULTS: CONCLUSIONS: NAC-SOX130 is a feasible therapy for older patients, although systemic management and careful monitoring of adverse events are necessary.
|
Authors | Mitsuhiko Ota, Hiroshi Saeki, Hideo Uehara, Yoshiko Matsuda, Satoshi Tsutsumi, Tetsuya Kusumoto, Hisateru Yasui, Yasunari Ubukata, Shohei Yamaguchi, Hiroyuki Orita, Naoki Izawa, Saburo Kakizoe, Mototsugu Shimokawa, Tomoharu Yoshizumi, Yoshihiro Kakeji, Masaki Mori, Eiji Oki |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 28
Issue 9
Pg. 1166-1175
(Sep 2023)
ISSN: 1437-7772 [Electronic] Japan |
PMID | 37368093
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Copyright | © 2023. The Author(s). |
Chemical References |
|
Topics |
- Humans
- Aged
- Neoadjuvant Therapy
- Stomach Neoplasms
(drug therapy, surgery, pathology)
- Oxaliplatin
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects)
- Neoplasm Recurrence, Local
(surgery)
- Chemotherapy, Adjuvant
- Gastrectomy
|